Forest Ray

The University of Notre Dame spinout has developed molecular subtyping tests for colorectal and other cancers, and seeks partners to bring them to the clinic.

While year-over-year testing services declined, CareDx said recently completed studies, new drugs, and further payor coverage may drive growth.

Myriad's total revenue grew 23 percent year over year, driven by a strong quarter for hereditary cancer and prenatal testing.

A five-year, $4.6 million NCI grant will help the researchers advance their EFIRM electric field-based DNA detection platform toward potential regulatory approval.

The Branford, Connecticut-based company is preparing to launch a prostate cancer liquid biopsy test while in early discussions to expand its existing test into Japan.

Direct-to-consumer microbiome tests often go beyond what the research can support, but the large databases being generated by some companies are supporting diagnostic development.

Adapting to the coverage decision put a dent in test volumes, but the firm has implemented needed changes and expects to see gains toward the end of the year.

The company realized Q2 revenues from a recent surge in carrier testing volumes and expressed confidence in the potential inclusion of MRD testing in NCCN guidelines.

Transplant surgeons and patient advocates fear that the decision to reimburse only one test per patient visit will impede patient care and worsen healthcare disparities.

UCSF researchers developed a polygenic score for PSA production that may be able to help account for individual variation in PSA levels.